Ernexa Therapeutics (ERNA) Projected to Release Earnings on Friday

Ernexa Therapeutics (NASDAQ:ERNA) is anticipated to announce its resultson Friday, November 6th. Analysts expect the company to post earnings of ($3.84) per share for the quarter.

Ernexa Therapeutics (NASDAQ:ERNA) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.10). On average, analysts expect Ernexa Therapeutics to post ($18.02) EPS for the current fiscal year and ($1.86) EPS for the next fiscal year.

Ernexa Therapeutics Price Performance

Ernexa Therapeutics stock opened at $1.98 on Thursday. Ernexa Therapeutics has a 12 month low of $1.84 and a 12 month high of $46.11. The business’s fifty day simple moving average is $3.13 and its two-hundred day simple moving average is $7.19.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Thursday, October 15th. Wall Street Zen cut shares of Ernexa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $30.00.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.